Hansoh Pharmaceutical (03692) Announces HS-10542 Capsule Receives NMPA Approval for Clinical Trials

Hansoh Pharma (03692) announced that HS-10542 Capsule, a Class 1 new drug independently developed by the Group, has received the clinical trial approval notice issued by the National Medical Products Administration (NMPA) of China. The capsule is planned to be used in clinical trials for paroxysmal nocturnal hemoglobinuria and immunoglobulin A nephropathy.